Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

Adele Green, V. Beral, R. Doll, C. Hermon, R. Peto, G. Reeves, L. Brinton, A. C. Green, P. Marchbanks, E. Negri, R. Ness, P. Peeters, M. Vessey, E. E. Calle, C. Rodriguez, L. Dal Maso, R. Talamini, D. Cramer, S. E. Hankinson, S. S. TworogerA. Chetrit, G. Hirsh-Yechezkel, F. Lubin, S. Sadetzki, P. Appleby, E. Banks, A. Berrington de Gonzalez, D. Bull, B. Crossley, A. Goodill, I. Green, J. Green, T. Key, R. Collins, C. A. Gonzalez, N. Lee, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, L. Titus-Ernstoff, B. J. Mosgaard, D. Yeates, J. Chang-Claude, M. A. Rossing, D. Thomas, N. Weiss, S. Franceschi, C. La Vecchia, H. O. Adami, C. Magnusson, T. Riman, E. Weiderpass, A. Wolk, L. A. Brinton, D. M. Freedman, P. Hartge, J. M. Lacey, R. Hoover, L. J. Schouten, P. A. van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, S. Graff-Iversen, R. Selmer, C. J. Bain, D. M. Purdie, V. Siskind, P. M. Webb, S. E. McCann, P. Hannaford, C. Kay, C. W. Binns, A. H. Lee, M. Zhang, P. Nasca, P. F. Coogan, L. Rosenberg, J. Kelsey, R. Paffenbarger, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, A. Tzonou, A. Dabancens, L. Martinez, R. Molina, O. Salas, M. T. Goodman, G. Laurie, M. E. Carney, L. R. Wilkens, A. Bladstrom, H. Olsson, R. B. Ness, J. A. Grisso, M. Morgan, J. E. Wheeler, J. Casagrande, M. C. Pike, R. K. Ross, A. H. Wu, M. Kumle, E. Lund, L. McGowan, X. O. Shu, W. Zheng, T. M M Farley, S. Holck, O. Meirik, H. A. Risch

    Research output: Contribution to journalArticlepeer-review


    Background: Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Methods: Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy. Findings: Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations among users of 4·4 and 5·0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian cancer risk (p
    Original languageEnglish
    Pages (from-to)303-314
    Number of pages11
    JournalThe Lancet
    Issue number9609
    Publication statusPublished - 26 Jan 2008


    Dive into the research topics of 'Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls'. Together they form a unique fingerprint.

    Cite this